[1] J.A.W. Hagemans, J. Rothbarth, G.H.W. van Bogerijen, E. van Meerten, J. Nuyttens, C. Verhoef, J.W.A. Burger, Treatment of Inguinal Lymph Node Metastases in Patients with Rectal Adenocarcinoma, Annals of surgical oncology, 26 (2019) 1134-1141.
[2] R.S. Shinde, N. Katdare, N.A.N. Kumar, R. Bhamre, A. Desouza, V. Ostwal, R. Engineer, A. Saklani, Impact of histological subtype on treatment outcomes in locally advanced rectal adenocarcinoma treated with neoadjuvant chemoradiation, Acta oncologica, 57 (2018) 1721-1723.
[3] F. Letaief, M. Nasri, M. Ayadi, K. Meddeb, A. Mokrani, Y. Yahyaoui, N. Chraiet, H. Raies, A. Mezlini, Potential predictive factors for pathologic complete response after the neoadjuvant treatment of rectal adenocarcinoma: a single center experience, Cancer biology & medicine, 14 (2017) 327-334.
[4] L.S. Lino-Silva, R.A. Salcedo-Hernandez, E.B. Ruiz-Garcia, A.M. Leon-Takahashi, L. Garcia-Perez, Outcome of young patients with rectal adenocarcinoma, Journal of gastrointestinal oncology, 8 (2017) 96-101.
[5] A. Merchea, S.M. Ali, S.R. Kelley, E. Duchalais, J.Y. Alabbad, E.J. Dozois, D.W. Larson, Long-Term Oncologic Outcomes of Minimally Invasive Proctectomy for Rectal Adenocarcinoma, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 22 (2018) 1412-1417.
[6] P. Renz, R.E. Wegner, S. Hasan, R. Brookover, G. Finley, D. Monga, M. Raj, J. McCormick, A. Kirichenko, Survival Outcomes After Surgical Management of the Primary Tumor With and Without Radiotherapy for Metastatic Rectal Adenocarcinoma: A National Cancer Database (NCDB) Analysis, Clinical colorectal cancer, (2019).
[7] S. Ahmed, C. Eng, Role of Chemotherapy in the Neoadjuvant/Adjuvant Setting for Patients With Rectal Adenocarcinoma Undergoing Chemoradiotherapy and Surgery or Radiotherapy and Surgery, Current oncology reports, 20 (2018) 3.
[8] R.Y. Tay, M. Jamnagerwalla, M. Steel, H.L. Wong, J.J. McKendrick, I. Faragher, S. Kosmider, I. Hastie, J. Desai, M. Tacey, P. Gibbs, R. Wong, Survival Impact of Adjuvant Chemotherapy for Resected Locally Advanced Rectal Adenocarcinoma, Clinical colorectal cancer, 16 (2017) e45-e54.
[9] M.S. Chiu, V. Verma, N.R. Bennion, A.R. Bhirud, J. Li, M.E. Charlton, C. Are, C. Lin, Comparison of outcomes between rectal squamous cell carcinoma and adenocarcinoma, Cancer medicine, 5 (2016) 3394-3402.
[10] W.M. Mendenhall, W.R. Rout, R.A. Zlotecki, S.E. Mitchell, R.D. Marsh, E.M. Copeland, 3rd, Conservative treatment of rectal adenocarcinoma, Hematology/oncology clinics of North America, 15 (2001) 303-319.
[11] Y. Hua, X. Ma, X. Liu, X. Yuan, H. Qin, X. Zhang, Identification of the potential biomarkers for the metastasis of rectal adenocarcinoma, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 125 (2017) 93-100.
[12] P. Kapur, Predictive biomarkers for response to therapy in advanced colorectal/rectal adenocarcinoma, Critical reviews in oncogenesis, 17 (2012) 361-372.
[13] J. McCain, The cancer genome atlas: new weapon in old war?, Biotechnology healthcare, 3 (2006) 46-51B.
[14] S. Bhattacharya, P. Dunn, C.G. Thomas, B. Smith, H. Schaefer, J. Chen, Z. Hu, K.A. Zalocusky, R.D. Shankar, S.S. Shen-Orr, E. Thomson, J. Wiser, A.J. Butte, ImmPort, toward repurposing of open access immunological assay data for translational and clinical research, Scientific data, 5 (2018) 180015.
[15] D. Caputo, M. Caricato, A. Coppola, V. La Vaccara, M. Fiore, R. Coppola, Neutrophil to Lymphocyte Ratio (NLR) and Derived Neutrophil to Lymphocyte Ratio (d-NLR) Predict Non-Responders and Postoperative Complications in Patients Undergoing Radical Surgery After Neo-Adjuvant Radio-Chemotherapy for Rectal Adenocarcinoma, Cancer investigation, 34 (2016) 440-451.
[16] S. Sadahiro, T. Suzuki, Y. Maeda, A. Tanaka, A. Kamijo, C. Murayama, Y. Nakayama, T. Akiba, Effects of preoperative immunochemoradiotherapy and chemoradiotherapy on immune responses in patients with rectal adenocarcinoma, Anticancer research, 30 (2010) 993-999.
[17] M. Hecht, M. Buttner-Herold, K. Erlenbach-Wunsch, M. Haderlein, R. Croner, R. Grutzmann, A. Hartmann, R. Fietkau, L.V. Distel, PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis, European journal of cancer, 65 (2016) 52-60.
[18] R. Liang, M. Wang, G. Zheng, H. Zhu, Y. Zhi, Z. Sun, A comprehensive analysis of prognosis prediction models based on pathwaylevel, genelevel and clinical information for glioblastoma, International journal of molecular medicine, 42 (2018) 1837-1846.
[19] J.Y. Hou, Y.G. Wang, S.J. Ma, B.Y. Yang, Q.P. Li, Identification of a prognostic 5-Gene expression signature for gastric cancer, Journal of cancer research and clinical oncology, 143 (2017) 619-629.
[20] B. Braschi, P. Denny, K. Gray, T. Jones, R. Seal, S. Tweedie, B. Yates, E. Bruford, Genenames.org: the HGNC and VGNC resources in 2019, Nucleic acids research, 47 (2019) D786-D792.
[21] Y. Xu, J. Chen, Z. Yang, L. Xu, Identification of RNA Expression Profiles in Thyroid Cancer to Construct a Competing Endogenous RNA (ceRNA) Network of mRNAs, Long Noncoding RNAs (lncRNAs), and microRNAs (miRNAs), Medical science monitor : international medical journal of experimental and clinical research, 25 (2019) 1140-1154.
[22] S. Hanzelmann, R. Castelo, J. Guinney, GSVA: gene set variation analysis for microarray and RNA-seq data, BMC bioinformatics, 14 (2013) 7.
[23] M.A. Amante, I.O. Real, G. Bermudez, Thyroid metastasis from rectal adenocarcinoma, BMJ case reports, 2018 (2018).
[24] T. Nishikawa, S. Ishihara, T. Ushiku, K. Hata, K. Sasaki, K. Murono, K. Yasuda, K. Otani, T. Tanaka, T. Kiyomatsu, K. Kawai, H. Nozawa, T. Watanabe, Anal metastasis from rectal adenocarcinoma, Clinical journal of gastroenterology, 9 (2016) 379-383.
[25] C. Weissenberger, G. Von Plehn, F. Otto, A. Barke, F. Momm, M. Geissler, Adjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: role of CEA and CA 19-9, Anticancer research, 25 (2005) 1787-1793.
[26] M. Demes, S. Scheil-Bertram, H. Bartsch, A. Fisseler-Eckhoff, Signature of microsatellite instability, KRAS and BRAF gene mutations in German patients with locally advanced rectal adenocarcinoma before and after neoadjuvant 5-FU radiochemotherapy, Journal of gastrointestinal oncology, 4 (2013) 182-192.
[27] W. Daskalaki, E. Wardelmann, M. Port, K. Stock, J. Steinestel, S. Huss, J. Sperveslage, K. Steinestel, S. Eder, Expression levels of hnRNP K and p21WAF1/CIP1 are associated with resistance to radiochemotherapy independent of p53 pathway activation in rectal adenocarcinoma, International journal of molecular medicine, 42 (2018) 3269-3277.
[28] B. Zhang, B. Cheng, F.S. Li, J.H. Ding, Y.Y. Feng, G.Z. Zhuo, H.F. Wei, K. Zhao, High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 36 (2015) 9411-9419.
[29] B. Zhang, B. Song, X. Wang, X.S. Chang, T. Pang, X. Zhang, K. Yin, G.E. Fang, The expression and clinical significance of CD73 molecule in human rectal adenocarcinoma, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 36 (2015) 5459-5466.
[30] T.I. Kopp, V. Andersen, A. Tjonneland, U. Vogel, Polymorphisms in NFKB1 and TLR4 and interaction with dietary and life style factors in relation to colorectal cancer in a Danish prospective case-cohort study, PloS one, 10 (2015) e0116394.
[31] Q. Wang, J. Qian, F. Wang, Z. Ma, Cellular prion protein accelerates colorectal cancer metastasis via the Fyn-SP1-SATB1 axis, Oncology reports, 28 (2012) 2029-2034.
[32] L. Zhou, H.F. Zhang, W. Ning, X. Song, X. Liu, J.X. Liu, Associations of adiponectin receptor 2 (AdipoR2) gene polymorphisms and AdipoR2 protein expression levels with the risk of colorectal cancer: A case-control study, Molecular medicine reports, 16 (2017) 3983-3993.
[33] A. Ling, A. Lofgren-Burstrom, P. Larsson, X. Li, M.L. Wikberg, A. Oberg, R. Stenling, S. Edin, R. Palmqvist, TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer, Oncoimmunology, 6 (2017) e1356143.
[34] S.B. Nadin, F.D. Cuello-Carrion, M.L. Sottile, D.R. Ciocca, L.M. Vargas-Roig, Effects of hyperthermia on Hsp27 (HSPB1), Hsp72 (HSPA1A) and DNA repair proteins hMLH1 and hMSH2 in human colorectal cancer hMLH1-deficient and hMLH1-proficient cell lines, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 28 (2012) 191-201.
[35] Z.N. Erdem, S. Schwarz, D. Drev, C. Heinzle, A. Reti, P. Heffeter, X. Hudec, K. Holzmann, B. Grasl-Kraupp, W. Berger, M. Grusch, B. Marian, Irinotecan Upregulates Fibroblast Growth Factor Receptor 3 Expression in Colorectal Cancer Cells, Which Mitigates Irinotecan-Induced Apoptosis, Translational oncology, 10 (2017) 332-339.
[36] M.D. Long, P.K. Singh, J.R. Russell, G. Llimos, S. Rosario, A. Rizvi, P.R. van den Berg, J. Kirk, L.E. Sucheston-Campbell, D.J. Smiraglia, M.J. Campbell, The miR-96 and RARgamma signaling axis governs androgen signaling and prostate cancer progression, Oncogene, 38 (2019) 421-444.
[37] M.T. Mizwicki, M. Fiala, L. Magpantay, N. Aziz, J. Sayre, G. Liu, A. Siani, D. Chan, O. Martinez-Maza, M. Chattopadhyay, A. La Cava, Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling, American journal of neurodegenerative disease, 1 (2012) 305-315.
[38] I.G. Ovsyannikova, N. Dhiman, I.H. Haralambieva, R.A. Vierkant, M.M. O'Byrne, R.M. Jacobson, G.A. Poland, Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes, Human genetics, 127 (2010) 207-221.
[39] A. Crisa, F. Ferre, G. Chillemi, B. Moioli, RNA-Sequencing for profiling goat milk transcriptome in colostrum and mature milk, BMC veterinary research, 12 (2016) 264.